Journal: Oncotarget

Article Title: Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer.

doi: 10.18632/oncotarget.9719

Figure Lengend Snippet: Figure 2: ERRβ/γ agonist DY131 is growth-inhibitory in breast cancer cells. A. Crystal violet staining of breast cancer and non-transformed breast epithelial cell lines in the presence or absence of the indicated concentrations of DY131 or DMSO control over time. N = 6 for a representative assay performed in sextuplicate, two-way ANOVA with Bonferroni post-tests in each cell line vs. DMSO control at Day 10/11. B. Clonogenic survival assay for MCF7 and MDA-MB-231 cells seeded at low density and cultured for 13 d after a single, 24 h exposure to the indicated concentrations of DY131. C-D. Representative Western blot analysis of basal ERRβsf, ERRβ2, and ERRγ expression in non-transformed mammary epithelial and breast cancer cells. β2 and βsf positive controls are from MDA-MB-231 cells transiently transfected with the indicated cDNA. γ positive control is purified protein.

Article Snippet: Human ERRγ purified protein (transcript variant 2), was purchased from Origene (Rockville, MD).

Techniques: Staining, Transformation Assay, Control, Clonogenic Cell Survival Assay, Cell Culture, Western Blot, Expressing, Transfection, Positive Control, Purification